RANKL/TNFSF11/CD254 Protein, Human, Recombinant [TMPY-03364]

輸入に関する法規制チェックは、御見積のご依頼をいただいた際に行います。
法規制によっては、定価として記載の価格に追加の費用が発生する場合や供給出来ない場合がございますので、あらかじめご了承ください。

Synonyms	hRANKL2, ODF, OPGL, sOdf, OPTB2, TNFSF11, TRANCE, RANKL, tumor necrosis factor (ligand) superfamily, member 11, CD254
Characteristics	1. Immobilized human TNFSF11 at 2 μg/ml (100 μl/well) can bind human Osteoprotegerin hFc, The EC50 of human Osteoprotegerin hFc is 5-40 ng/ml. 2. The bioactivity of hRANKL was determined by measuring the ability of hRANKL to induce TRAP activity in Raw 264.7 cells. The ED50 for this effect is typically 1.5-7.5 ng/mL.
Endotoxin Level	< 1.0 EU/μg of the protein as determined by the LAL method.
Purity	86%
Description	RANKL/TNFSF11/CD254 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 20.5 kDa and the accession number is AAC51762.1.
Reference	Schwarz EM,et al.(2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther. 9 Suppl 1: S7.,Takayanagi H,et al.(2002) Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res. 4 Suppl 3: S227-32.,Nakashima T,et al.(2003) RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol. 15(3): 280-7.,Leibbrandt A,et al.(2008) RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 1143: 123-50.
URL	https://www.targetmol.com/recombinant-protein/rankl_protein_human_recombinant

バイオ製品Bio Products